Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNSS~ No worries here....I can wait till $2.
SNSS~ Alert.. Just hit $1
Thanks for the candid feedback on DARAD, much appreciated.
$heff, with DARAD now under $4 and R/S behind it..Down 12%.. Your thoughts on when does it become attractive?
DARAD~ Raising $10 million...PR below
DARA BioSciences to Raise Up to $10,000,000 Through Public Offering
8:45a ET May 17, 2010 (GlobeNewswire)
DARA BioSciences, Inc. (the "Company") (Nasdaq:DARAD) announced today that it has commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. The company intends to grant the underwriter in the offering an option to purchase up to $1.5 million of additional units to cover any over-allotments.
The proceeds received by the Company from the offering will be used for the ongoing development of its lead candidates and working capital.
C.K. Cooper & Company will act as the underwriter for the offering. The offering is being made only by means of a prospectus, copies of which may be obtained from the offices of C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, CA 92612, or by calling 1-888-477-9301. Electronic copies of the prospectus are available on the Securities and Exchange Commission's Web site at www.sec.gov.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release does not constitute an offer to sell these securities or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DARA
DARA BioSciences, Inc. is a Raleigh, North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA and are in clinical study. The Company has a pipeline of diverse drug candidates at various stages of development, with 82 granted patents and 56 pending applications (U.S. and foreign). The first drug candidate, KRN5500, has successfully completed a Phase 2 clinical trial treating cancer patients for neuropathic pain. KRN5500 met its primary endpoint and was statistically significantly (p=0.03) better than placebo. A second Phase 2 clinical trial is planned to start during the second half of 2010. The second drug candidate DB959 is a highly selective, non-thiazolidinedione (TZD), first-in-class dual PPAR (peroxisome proliferator activated receptor) delta/gamma agonist in development for type II diabetes. A Phase 1 clinical study for DB959 is underway, and the Company plans to announce results in the second half of 2010. In addition, DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities. PPAR receptors are found throughout the human body and recent publications report that PPAR agonists may be useful in the treatment of Alzheimer's disease, cystic fibrosis, liver disease, and a variety of autoimmune diseases. Because its diverse PPAR library has the potential to address the unmet medical needs of these diseases, the company plans to explore several of these indications.
All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors the risk that the Company is unsuccessful in completing the contemplated offering, and the other risk factors identified in the prospectus for the offering and the other documents DARA has filed, or will file, with the Securities and Exchange Commission ("SEC"). Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: DARA BioSciences, Inc.
CONTACT: Cameron Associates, Inc.
Kevin McGrath
212.245.4577
Kevin@cameronassoc.com
C.K. Cooper & Company
Bilal Basrai
312.794.7742
bbasrai@ckcooper.com
SNSS~ Solid accumulation this morning, almost traded 1/3 avg volume... I added some too.
ALXA 3.46 now.... rebounding nicely
In ALXA @ 3.38... will bounce some by EOD.
HMIT~ HOD..Last call...1 left @ 0019
EPGL~ Not filling me @ 0001..Hmmmm!
RPC~ Higher... Watched the L2 and ticker all day yesterday...Someone is loading BIG TIME....1/3 of O/S traded yesterday...enough reason for me...Market down 180 and it has not crashed...not the typical P&D. Watch the market turn and you'll see easy 10% from here, Imo.
In RPC again now.. will close higher.
Everyday going forward we will see more of this EURO selling, the reality of EURO failure has just started to sink in, Imo.
TIVO~ Fear n panic because of the court hearing again.
Nah bro, not so high, Pigs get slaughtered. I'll take my 10%+
Sarkozy threatened to pull France out of Eurozone....hmmmmmm. Is this the end of the beginning?
TIVO~ News out.. This will jump right back up. Its only a hearing, not a ruling. Market overreacting... jmho.
Yeppers... Bring on that Grand again, lol...
In TIVO @ 10.65 for the bounce.
MBHI~Cashed out my RPC too early today @ 1.34 gotta put the money to work. They'll take it down hard at open.....looking forward to adding at the plunge...MBHI ATM will be open and working tomorrow..lol!
MBHI~ AH .15 printing. DJN wire saying Recievership likely Friday. Gonna pick up a few at the plunge tomorrow AM.
SNSS~ Sticking with this one based on chart, not gonna cut it loose yet. Too much momentum with ASCO coming up.
SNSS~ In for the swing, shorts covering... Imo.
FFGO~ This is how 0001 stocks move, before they breakout.. churning back and forth in 0001-0002 territory. Just look at the past few movers in subpenny land in the last few months. With gold @ $1238..FFGO has got no where to go but UP. Hope you don't miss the action...Hahahaha I got my shares...Gltu
SNSS~ Agreed on chart.. Definitely looks ready, I picked up a starter here too.
CLDX~ Thanks again bud, took some profits though on this nice run.
CLDX~ $9.13 now.. Alerted Yesterday...Weeeeeeeeeee!
MBHI~ On high watch for Q and bounce play.. They better get their act together for the financing since Friday is around the corner & you know what that means for weak banks>>>
MBHI~ Totally agree Langlui, just gonna be a quick swing for me.. if at all. I have gotten my 100% before on the last Parabolic run. ALXA on watch today... new 52 week high last few days... and analyst upgrade as well. Keep it on watch.. Gltu
MBHI~ Watching... for the low and paninc selling....
CLDX~ $9 gettin hit now...Yeah>>>> Just keeps on going>>>
CLDX~ Gonna take out $9 in a hurry here>>>
CLDX~ new 90 day high, Blue sky breakout. ASCO persentations coming up.
CLDX~ Thanks for the Alert! I like what I see, and Institutional ownership should start increasing as we get closer to ASCO. Beautiful chart too with a new 90 day high today. I added some this morning. ASCO presentations schedule below:
The company will be presenting promising data from the following studies:
PF-04948568 (CDX-110) in Glioblastoma Multiforme:
Poster Discussion Session
-------------------------
Abstract Title: Interim data for ACT III: Phase II trial of PF-
04948568 (CDX-110) in combination with temozolomide (TMZ) in
patients (pts) with glioblastoma (GBM).
Presentation Date/Time: Saturday, June 5, 2010; 8:00 AM - 12:00
PM with poster discussion from 12:00 - 12:15 PM
Presenter: Rose Lai, MD MSc, Assistant Professor of Neurology,
The Neurological Institute of Columbia University, Brain Tumor
Center
Abstract Control Number: 53835
Permanent Abstract ID: 2014
Location: S103, Poster Board #6, with discussion in S100b
CDX-011 in Advanced Melanoma:
Poster Discussion Session
-------------------------
Abstract Title: Frequent dosing and GPNMB expression with CDX-
011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in
patients with advanced melanoma.
Presentation Date/Time: Monday, June 7, 2010; 8:00 AM - 12:00 PM
with poster discussion from 11:00 AM - 12:00 PM
Presenter: Omid Hamid, MD, The Angeles Clinic and Research
Institute, Santa Monica, CA
Abstract Control Number: 51525
Permanent Abstract ID: 8525
Location: S403, Poster Board #13, with discussion in S406 (Vista
Room)
CDX-011 in Breast Cancer:
General Poster Session
----------------------
Abstract Title: Correlation of GPNMB expression with outcome in
breast cancer (BC) patients treated with the antibody-drug
conjugate (ADC), CDX-011 (CR011-vcMMAE).
Presentation Date/Time: Saturday, June 5, 2010; 2:00 PM -6:00
PM
Presenter: Mansoor N. Saleh, MD, Georgia Cancer Specialists,
Atlanta, GA
Abstract Control Number: 51830
Permanent Abstract ID: 1095
Location: S Hall A2, Poster Board #30C
CDX-1307 in Muscle-invasive Bladder Cancer:
Trials in Progress Poster Session
---------------------------------
Abstract Title: A randomized phase II study of a novel antigen-
presenting cell-targeted hCG-beta vaccine (the CDX-1307
regimen) in muscle-invasive bladder cancer.
Presentation Date/Time: Monday, June 7 2010; 8:00 AM - 12:00 PM
Presenter: Deborah Ann Bradley, MD, Duke University Medical
Center, Durham, NC
Abstract Control Number: 51567
Permanent Abstract ID: TPS228
Location: S Hall A2, Poster Board #41G
Abstracts can be accessed after May 20, 2010 through the ASCO website, www.asco.org. All posters will be accessible from Celldex's website at www.celldextherapeutics.com after they are presented.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of CDX-110, CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital on acceptable terms, or at all; our ability to adapt APC Targeting Technology(TM) to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; our development partners' willingness to make announcements with respect to co-developed products; the uncertainties inherent in clinical testing; our ability to manage research and development efforts for multiple products at varying stages of development; Pfizer's and our strategy and business plans concerning the continued development and commercialization of CDX-110; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; our ability to successfully integrate the businesses, multiple technologies and programs of CuraGen and Celldex; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Celldex Therapeutics, Inc.
MBRK~ Just unbelievable buying action. Someone just keeps on loading more on every small dip.
MBRK~ Alert! Up 19% Now. Approaching New HOD on Heavy Volume. Someone is seeing value for shareholders in BK, Jmho.
MBRK~ Up 15% @ .14 ALERT! Volume keeps pouring in...hmmmmm
So you in...? or would you be watching from sidelines when we cashout after FFGO sale is announced, hahaha!!!
FFGO~ Yes & Making BIG $$$$. Actually back then the pps went to 0009 before coming down. I missed the top..still making 25K is not bad...